Carregant...

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

Immunotherapy with programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Diagn Ther
Autors principals: Hunter, Katerina Ancevski, Socinski, Mark A., Villaruz, Liza C.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773410/
https://ncbi.nlm.nih.gov/pubmed/29119407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40291-017-0308-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!